glp-1 agonist cardiovascular outcomes Real-World Evidence for Receptor Agonists Across the CKD Spectrum – AJKD Blog Cardiovascular outcomes in major trials

Shivaswamy V, Boerner B, Larsen J

Ghrelin, glucagon-like peptide-1, and peptide YY secretion in patients with and without weight regain during long-term follow-up after bariatric surgery: a cross-sectional study

GLP-1 secretion is enhanced directly in the ileum but indirectly in the duodenum by a newly identified potent stimulator, zein hydrolysate, in rats

Of the 100 patients initially enrolled in the study, 11 were classified as dropouts due to being lost to follow-up, while 4 patients discontinued treatmentone due to hypoglycemia, one due to lack of efficacy, and two due to challenges in accessing the medicationresulting in 85 patients completing therapy until the studys conclusion

OR odds ratio

GLP-1 receptor agonists also improve metabolism: Promote insulin sensitivity and better blood sugar control Help patients lose and keep off weight Lower cholesterol and triglycerides This is why so many patients with arthritis are reporting less joint swelling, less pain, fatigue, better energy, and overall well-being